Neutrophil-to-lymphocyte ratio associates with intratumoral myeloid predominance and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma

被引：0
|
作者：
Morimoto, Hiroki
Tsujikawa, Takahiro
Miyagawa-Hayashino, Aya
Kimura, Alisa
Saburi, Sumiyo
Mitsuda, Junichi
Yoshimura, Kanako
Ohmura, Gaku
Mukudai, Shigeyuki
Nagao, Hikaru
Sugiyama, Yoichiro
Saya, Shibata
Ogi, Hiroshi
Konishi, Eiichi
Itoh, Kyoko
Hirano, Shigeru
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4453
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Prognostic value of the neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma
    Wong, B. Y. Winson
    Stafford, Nicholas D.
    Green, Victoria L.
    Greenman, John
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1903 - E1908
  • [22] Low neutrophil-to-lymphocyte ratio is a negative prognosticator in oral squamous cell carcinoma
    Mattavelli, D.
    Lombardi, D.
    Missale, F.
    Calza, S.
    Battocchio, S.
    Paderno, A.
    Bozzola, A.
    Vermi, W.
    Piazza, C.
    Nicolai, P.
    RADIOTHERAPY AND ONCOLOGY, 2019, 132 : 97 - 97
  • [23] The Predictive Value of Pretreatment Neutrophil-To-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma
    Miao-Fen Chen
    Ping-Tsung Chen
    Feng-Che Kuan
    Wen-Cheng Chen
    Annals of Surgical Oncology, 2019, 26 : 190 - 199
  • [24] Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
    Chikuie, Nobuyuki
    Hamamoto, Takao
    Ueda, Tsutomu
    Taruya, Takayuki
    Kono, Takashi
    Furuie, Hiromi
    Ishino, Takashi
    Takeno, Sachio
    ACTA MEDICA OKAYAMA, 2021, 75 (03) : 335 - 343
  • [25] Prognostic value of posttreatment neutrophil lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy
    Kim, Do Young
    Kim, In Su
    Park, Sang Gyu
    Kim, Hyojeong
    Choi, Young Jin
    Seol, Young Mi
    AURIS NASUS LARYNX, 2017, 44 (02) : 199 - 204
  • [26] Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients
    Li, Jun-Liang
    Hsieh, Tsai-Ling
    Ou, Ming-Che
    Lin, Frank Cheau-Feng
    Tsai, Stella Chin-Shaw
    ORAL ONCOLOGY, 2022, 126
  • [27] Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab
    Tachinami, Hidetake
    Tomihara, Kei
    Yamada, Shin-ichi
    Ikeda, Atsushi
    Imaue, Shuichi
    Hirai, Hideaki
    Nakai, Hiromi
    Sonoda, Tomoko
    Kurohara, Kazuto
    Yoshioka, Yukio
    Hasegawa, Takumi
    Naruse, Tomofumi
    Niiyama, Takashi
    Shimane, Tetsu
    Ueda, Michihiro
    Yanamoto, Souichi
    Akashi, Masaya
    Umeda, Masahiro
    Kurita, Hiroshi
    Miyazaki, Akihiro
    Arai, Naoya
    Hayashi, Ryuji
    Noguchi, Makoto
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2023, 61 (04): : 320 - 326
  • [28] Neutrophil-to-lymphocyte ratio as a predictive indicator of the response to nivolumab in oral squamous cell carcinoma
    Tachinami, Hidetake
    Tomihara, Kei
    Sakurai, Kotaro
    Noguchi, Makoto
    CANCER SCIENCE, 2022, 113 : 1747 - 1747
  • [29] Reply regarding prognostic value of neutrophil-to-lymphocyte ratio in laryngeal squamous cell carcinoma
    Wong, B. Y. Winson
    Stafford, Nicholas D.
    Green, Victoria L.
    Greenman, John
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (03): : 615 - 615
  • [30] Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma
    Ohsawa, Manato
    Hamai, Yoichi
    Emi, Manabu
    Ibuki, Yuta
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Kitasaki, Nao
    Okada, Morihito
    ANTICANCER RESEARCH, 2022, 42 (03) : 1499 - 1507
12345